EQL Pharma has today entered into an exclusive out-licensing agreement with a leading European Company in ADHD for EQL's proprietary product Mellozzan (melatonin) for Germany, the United Kingdom, Austria, Switzerland, Finland, Denmark and Norway. The agreement applies to tablets in six different strengths as well as an oral solution, where the latter is newly developed and ready to be sent to authorities for registration.
 

Mellozzan is a medicine given to children with sleep disorders who have ADHD and where sleep hygiene measures are not enough. It can also be given as a short-term treatment to adults with sleep disorders caused by jet lag. Mellozzan was launched by EQL in Sweden in 2021, and EQL's ambition is to offer the product to all other interesting markets in Europe via out-licensing.
 

The Licensee is one of Europe's leading pharmaceutical companies in the treatment of ADHD with  extensive resources in sales and marketing in the licensed countries.

"We are extremely happy and proud that we will now be able to offer Mellozzan in countries such as Germany and the UK where there is currently no corresponding product for treating sleep disorders in children with ADHD. In Sweden, melatonin treatment for children with ADHD and sleep disorders has reached a total treatment volume of well over 60 million tablets per year, distributed among some original players, including Mellozzan. We see our Licensee as the perfect partner who has the know-how, the network of specialists and with the interface to authorities, that is necessary to reach this large group of patients in a fast and safe way in the important markets of Europe." says Christer Fåhraeus, CEO of EQL.

The agreement includes close to 500,000 EUR in down payment and regulatory milestones. The royalty on sales is well into the double-digit domain. The launch of Mellozzan will take place over a period of one to three years from today's date, mainly governed by differences in processing times at different countries' authorities for registration and reimbursement.EQL Pharma has advanced negotiations regarding Mellozzan with other companies for additional countries in and outside of Europe.

This disclosure contains information that EQL Pharma is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 22-03-2022 08:30 CET.

For further information, please contact:
Christer Fåhraeus
CEO, EQL Pharma AB (publ)

Phone: +46 (0) 705 - 60 90 00
E-mail: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com

EQL Pharma AB (publ) in short

EQL Pharma AB specializes in developing and selling niche pharmaceuticals. The company currently has more than 20 niche generics (ie generics with limited competition apart from the reference pharmaceutical) approved in the Nordic markets and a couple of originals. In addition to these, there is a significant pipeline of mainly niche generics for launch in 2022 and beyond. The business is currently entirely focused on prescription pharmaceuticals, including hospital products, in the Nordic region and in selected European markets. EQL Pharma AB conducts its operations in Lund and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and pharmaceutical companies in the EU and Asia, among others.

https://news.cision.com/eql-pharma/r/eql-pharma-out-license-mellozzan-to-a-leading-european-company-in-adhd,c3529530

https://mb.cision.com/Main/11664/3529530/1551699.pdf

(c) 2022 Cision. All rights reserved., source Press Releases - English